PsychRights^®
                   Law Project for
              Psychiatric Rights

ADHD (& Stimulant "Treatment")

• Reanalyzing a Randomized Controlled Trial of Combination Antidepressant Treatment With Mirtazapine: Confidence Intervals Suggest Substantial Uncertainty, by Jeffrey R. Lacasse, PhD, Ethical Human Psychology and Psychiatry, Vol. 13, No.2;149-154, 2011.
• Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate, by Donald R. Mattison,Tony M. Plant, Hui-Min Lin, Hung-Chia Chen, James J. Chen, Nathan C. Twaddle, Daniel Doergec William Slikker, Jr., Ralph E. Patton, Charlotte E. Hotchkiss, Ralph J. Callicott, Steven M. Schrader, Terry W. Turner, James S. Kesner, Benedetto Vitiello, Dayton M. Petibone, and Suzanne M. Morris, Proceedings of the National Academy of Sciences (PNAS) (2011)
• MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study, by Brooke S.G. Molina, Ph.D., Stephen P. Hinshaw, Ph.D., James M. Swanson, Ph..D., L. Eugene Arnold, M.D., M.Ed., Benedetto Vitiello, M.D., Peter S. Jensen, M.D., Jeffery N. Epstein, Ph.D., Betsy Hoza, Pn.D., Lily Hechtman, M.D., Howard B. Abikoff, Ph.D., Glen R. Elliott, Ph.D., M.D., Laurence L. Greenhill, M.D., Jeffrey H. Newcorn, M.D., Karen C. Wells, Ph.D., Timothy Wigal, Ps.D., Robert D. Gibbons, Ph.D., Kwan Hur, Ph.D., Patricia R. Houck, M.S., and the MTA Cooperative Group, Journal of the American Academy of Child and Adolescent Psychiatry, 48 (2009):484-500.
• Sudden Death and Use of Stimulant Medications in Youths, by  Madelyn S. Gould, Ph.D., M.P.H.; B. Timothy Walsh, M.D.; Jimmie Lou Munfakh, B.A.; Marjorie Kleinman, M.S.; Naihua Duan, Ph.D.; Mark Olfson, M.D., M.P.H.; Laurence Greenhill, M.D.; and Thomas Cooper, M.A., American Journal of Psychiatry (2009).
• Dr. Grace E. Jackson Affidavit on  John R. Weisz and Peter S. Jensen, "Efficacy and Effectiveness of Child and Adolescent Psychotherapy and Pharmacotherapy," Mental Health Services Research 1:3 (1999): 125-157.
• September 25, 2008 FDA Warning Letters to Drug Companies Regarding False & Misleading Advertising:
  • Adderal XR (Shire)
    • Offending Promotional Material
  • Concerta (Johnson & Johnson)
    • Offending Promotional Material
  • Focalin XR (Novartis)
    • Offending Promotional Material
  • Methylin (Mallincrodt)
    • Offending Promotional Material
  • Strattera (Lilly)
    • Offending Promotional Material
• Cardiovascular Monitoring of Children and Adolescents with Heart Disease Receiving Stimulant Drugs, A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing, Victoria L. Vetter, Josephine Elia, Christopher Erickson, Suart Berger, Nathan Blum, Karen Uzark and Catherine L. Webb,  American Heart Association, Circulation DOI:10.1161/CirculationAHA,107.189473, with Top Ten Things to Know: Cardiovascular Monitoring of Children and Adolescents with Heart Disease Receiving Stimulant Drugs.
• ADHD Drugs and Cardiovascular Risk, by Steven E. Nissen, New England Journal of Medicine, N Engl J. Med Vol, 354 No. 14:1445-1448 (2006), with May 25, 2006 Correction, Vol. 354, No. 21, 2296-2298 (2006). 
  • (Audio) Interview with Dr. Steven Nissen on the cardiovascular risks associated with ADHD drugs.
• A Medication-Free Parent Management Program for Children Diagnosed as ADHD, by David Stein, Ph.D., Ethical Human Sciences and Services, Vol. 1, No. 1, 1999.  In this study, at the 1-year-follow-up, all 37 patients who had been diagnosed with ADHD and treated through the Caregivers Skill Program rather than the standard medication treatment no longer met DSM-IV criteria for ADHD.
• Stefan P Kruszewski, MD, & Steven G. Klotz, M.D., on Modafinil: Mischaracterization (Provigil) and Joseph Biederman, M.D.'s response, in J Clin Psychiatry 68:6, June 2007
• Stimulant-Related Reductions of Growth Rates in the PATS, by James Swanson, Ph.D., Laurence Greenhill, M.D., Tim Wigal, Ph.D., Scott Kollins, Ph.D., Annamarie Stehli, M.P.H., Mark Davies, M.P.H., Shirley Chuang, M.S., Benedetto Vitiello, M.D., Anne Skrobala, M.A., Kelly Posner, Ph.D., Howard Abikoff, Ph.D., Melvin Oatis, M.D., James Mccracken, M.D., James Mcgough, M.D., Mark Riddle, M.D., Jaswinder Ghuman, M.D., Charles Cunningham, Ph.D., and Sharon Wigal, Ph.D., American Academy of Child and Adolescent Psychiatry 45:11, November 2006.
• Psychiatric Adverse Events Associated with Drug Treatment of ADHD: Review of Postmarketing Safety Data, Memorandum by Food and drug Administration, Division of Drug Risk Evaluation Review Team to Thomas Laughren, Director of Division of Psychiatrict Products.
• Euphorigenic and Abusive Properties of Modafinil, by Stefan P. Kruszewski, M.D., American Journal of Psychiatry, Am J Psychiatry 163:3, March 2006
• Health Canada "Dear Health Care Letter" regarding the heart damaging characteristics of ADHD drugs, May 2006.
• Associated Press, February 10, 2006: FDA Panel recommends "Black Box" warning regarding lethal potential of ADHD Drugs (Ritalin, etc.).
• Grace E. Jackson, "Cybernetic Children," as published in Making and Breaking Children's Lives (Ross on Wye: PCCS Books, 2005).
• ADHD and the Meaning of Evidence, by Barry Turner, Lecturer in Medical Ethics and Law at the University of Lincoln, United Kingdom, Criminal Litigator and Mental Health Law Consultant.
• Methylphenidate-Induced Neuropathology in the Developing Rat Brain: Implications for Humans (Editorial), by Jonathon Leo, Ph.D., Ethical Human Psychology and Psychiatry, Volume 7, Number 2, Summer 2005
• What the Multimodal Treatmeht Study Really Discovered About Intervention for Children Diagnosed With ADHD: Implications for Early Childhood, by Brian Kean, Ethical Human Psychology and Psychiatry, Volume 6, Number 3, Fall/Winter 2004: 193-200.
• Aggression, Mania and and Hypomania Induction Associated With Atomoxetine (Strattera), by Theodore A. Henderson and Keith Hartman, Pediatrics, Vol. 114 No. 3 (2004), pp. 895-896.
• Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD, by Nora D. Volkow, M.D. & James M . Swanson, Ph .D., Am/ Psychiatry 76011, November 2003: 1909-1918.
• Student Perceptions of Methylphenidate Abuse at a Public Liberal Arts College, by Quinton Babcock, BA ; Torn Byrne, PhD, Journal of American College Health, Vol 49, November, 2000: 143-145.
• Broken Brains or Flawed Studies?  A Critical Review of ADHD Neuroimaging Research, by Jonathon Leo and David Cohen, The Journal of Mind and Behavior, Winter 2003, Volume 24, Number 1, pp 29-56.  This review of studies on ADHD and neuroimaging finds that most of them can not rule out that the differences observed are medication caused and the others "inexplicably avoided making straightforward comparisons" that could have given information on this issue.
• ADHD among American Schoolchildren: Evidence of Overdiagnosis and Overuse of Medication, by Gretchen B. LeFever and Andrea P. Arcona - Center for Pediatric Research, Eastern Virginia Medical School and Children's Hospital of the King's Daughters David O. Antonuccio - University of Nevada School of Medicine, Veterans Affairs Sierra Nevada Health Care System, The Scientific Review of Mental Health Practice, Spring/Summer 2003, Vol.2, No.1.
• Stimulant Treatment as a Risk Factor for Nicotine Use and Substance Abuse, by Nadine M. Lambert, Ph .D., University of California at Berkeley,  Graduate School of Education inn Jensen, P . S. & Cooper, J . R. (Eds.). (2002), Attention Deficit Hyperactivity Disorder: State of the Science ; Best Practices . (pp 18-1 to 18-24) Kingston, NJ : Civic Research Institute.
• The Ethics and Science of Medicating Children, by Jacqueline A. Sparks, Ph.D., Center for Family Services and Barry L. Duncan, Psy.D., Institute for the Study of Therapeutic Change makes several concise points about the adhd literature and critiques the main study used to support drug therapy.
• ADHD: Total, 100% Fraud, By Fred A. Baughman Jr., Neurologist, Pediatric Neurologist, Fellow, American Academy of Neurology
• Attention-Deficit Hyperactivity Disorder (ADHD) As Fraud, by Fred A. Baughman Jr., M. D., Neurologist, Pediatric Neurology, published La Catarsis de Quiron. Revista de Psicologia 2(1), 2002.
• Ritalin (Methylphenidate): Clinical Experiences, by P. B. Percheson, M.D., F.R.C.P., John J. Carroll, B.A., M.D., C.M., and Guy Screech, M.A., M. B., B.Chir, Canadian Anaethetists' Society Journal, Vol 6, No.3:227-282 (1959).

FAIR USE NOTICE: These links may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is used for non-profit educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.  Any copyright owner who objects to the use of their copyrighted material should send an e-mail to webmaster@psychrights.org.

Last modified 11/14/2011
Copyright © 2003-2011 Law Project for Psychiatric Rights. All Rights Reserved